SUTRO BIOPHARMA, INC. (STRO) Cash and securities
- Total cash · latest quarter (USD): Value $164.35M; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $164.35M | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. $54.34M + $110.01M ≈ $164.35M |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 54.34M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 110.01M USD | Marketable Securities, Current |
| Cash and current securities | 164.35M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | $164.35M | (m) | $54.34M | $110.01M | (m) |
| 2026-03-31 | $202.56M | (m) | $73.68M | $128.88M | (m) |
| 2025-12-31 | $141.43M | (m) | $58.13M | $83.30M | (m) |
| 2025-09-30 | $167.59M | (m) | $65.93M | $101.67M | (m) |
| 2025-06-30 | $205.13M | (m) | $64.03M | $141.11M | (m) |
| 2025-03-31 | $248.97M | (m) | $106.23M | $142.74M | (m) |
| 2024-12-31 | $316.89M | (m) | $190.30M | $126.59M | (m) |
| 2024-09-30 | $388.25M | (m) | $174.58M | $213.68M | (m) |
| 2024-06-30 | $375.57M | (m) | $90.79M | $284.78M | (m) |
| 2024-03-31 | $267.60M | (m) | $65.22M | $202.38M | (m) |
| 2023-12-31 | $333.68M | (m) | $69.27M | $264.41M | (m) |
| 2023-09-30 | $321.11M | (m) | $81.83M | $239.27M | (m) |
| 2023-06-30 | $358.29M | (m) | $235.09M | $123.20M | (m) |
| 2023-03-31 | $251.47M | (m) | $62.47M | $188.99M | (m) |
| 2022-12-31 | $302.34M | (m) | $47.25M | $255.09M | (m) |
| 2022-09-30 | $287.34M | (m) | $96.78M | $190.56M | (m) |
| 2022-06-30 | $191.63M | (m) | $79.11M | $112.51M | (m) |
| 2022-03-31 | $171.40M | (m) | $28.90M | $142.50M | (m) |
| 2021-12-31 | $160.76M | (m) | $30.41M | $130.34M | (m) |
| 2021-09-30 | $189.94M | (m) | $30.71M | $159.23M | (m) |
| 2021-06-30 | $223.42M | (m) | $56.39M | $167.03M | (m) |
| 2021-03-31 | $220.27M | (m) | $55.82M | $164.46M | (m) |
| 2020-12-31 | $326.49M | (m) | $206.15M | $120.34M | (m) |
| 2020-09-30 | $202.36M | (m) | $64.37M | $137.99M | (m) |
| 2020-06-30 | $201.36M | (m) | $65.35M | $136.01M | (m) |
| 2020-03-31 | $115.39M | (m) | $43.56M | $71.83M | (m) |
| 2019-12-31 | $117.86M | (m) | $4.96M | $112.90M | (m) |
| 2019-09-30 | $125.16M | (m) | $11.95M | $113.21M | (m) |
| 2019-06-30 | $153.16M | (m) | $19.39M | $133.77M | (m) |
| 2019-03-31 | $170.57M | (m) | $26.62M | $143.95M | (m) |
| 2018-12-31 | $204.49M | (m) | $125.30M | $79.19M | (m) |
| 2018-09-30 | $122.95M | (m) | $41.35M | $81.60M | (m) |
| 2018-06-30 | (m) | (m) | $25.42M | (m) | (m) |
| 2018-03-31 | (m) | (m) | $6.63M | (m) | (m) |
| 2017-12-31 | (m) | (m) | $22.02M | (m) | (m) |
| 2017-09-30 | (m) | (m) | $25.41M | (m) | (m) |
| 2016-12-31 | (m) | (m) | $11.59M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |